Ibrutinib as first line therapy for mantle cell lymphoma: A multicentre, real-world UK study
Description
During the Covid-19 pandemic, ibrutinib +/- rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. As limited data are available in this setting, we conducted an observational cohort study